NEWS
Quoin Pharmaceuticals to Initiate Clinical Study for Peeling Skin Syndrome
Quoin Pharmaceuticals (NASDAQ: QNRX) has announced plans to initiate a clinical study in New Zealand to evaluate QRX003 for Peeling Skin Syndrome (PSS), a rare autosomal disease with no approved treatment. The study will focus on a pediatric patient, with the company actively exploring additional clinical sites in other countries.
QRX003, Quoin's most advanced pipeline product, is already being tested in two late-stage clinical trials for Netherton Syndrome (NS) in the United States under an FDA-approved IND. The company aims to expand QRX003's development into PSS, leveraging potential similarities in the diseases' mechanisms. This move aligns with Quoin's strategy to broaden QRX003's applications in rare and orphan diseases.
QRX003, Quoin's most advanced pipeline product, is already being tested in two late-stage clinical trials for Netherton Syndrome (NS) in the United States under an FDA-approved IND. The company aims to expand QRX003's development into PSS, leveraging potential similarities in the diseases' mechanisms. This move aligns with Quoin's strategy to broaden QRX003's applications in rare and orphan diseases.
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only.
Read more
Comment
Sign in to post a comment
Spread kindness and love. Life is short. Don’t let greed eat you.
1156Followers
73Following
8061Visitors
Follow